Live Breaking News & Updates on Folder With

Stay updated with breaking news from Folder with. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Immunotherapy vs Chemoimmunotherapy in Older Adults With Advanced NSCLC

1. Adding chemotherapy to immunotherapy did not prolong OS or PFS, with non-significant differences in HR. 2. Grade 3 or higher immune-related adverse events occurred in 24.3% and 17.9% in the ICI-chemotherapy and ICI-alone groups. Evidence Rating Level: 2 (Good) Study Rundown: Immune checkpoint inhibitors (ICIs) have significantly improved outcomes in non-small cell lung cancer ....

Rating Level , Clinical Outcomes , Toxic Effects , Folder With ,